#trialdesign search results

Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephtwitter @VladoPerkovic @GlomCon buff.ly/MGvRVem

Neph_Times's tweet image. Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephtwitter @VladoPerkovic @GlomCon buff.ly/MGvRVem

What difference does it make to analyse a crossover trial as a parallel-group trial? Data from doi.org/10.1007/s00394… 24 hours of a low-carbohydrate diet on fasting glucose concentrations @AaronHengist #lowcarb #science #trialdesign #stats

Gonzalez_JT's tweet image. What difference does it make to analyse a crossover trial as a parallel-group trial?  

Data from doi.org/10.1007/s00394…

24 hours of a low-carbohydrate diet on fasting glucose concentrations

@AaronHengist 

#lowcarb #science #trialdesign #stats

This approach can be adopted within phase 3 trials. Trialists should address regulatory, payer, institution, clinician, patient requirements within the phase 3 trial design so that the #evidence generated is fit for purpose👇🏽 3/ authors.elsevier.com/a/1k2Nc2d9GH%7… #TrialDesign

hvanspall's tweet image. This approach can be adopted within phase 3 trials. 

Trialists should address regulatory, payer, institution, clinician, patient requirements within the phase 3 trial design so that the #evidence generated is fit for purpose👇🏽

3/
authors.elsevier.com/a/1k2Nc2d9GH%7…
#TrialDesign

Pleasure to participate in ⁦⁦⁦@sitcancer#SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from ⁦@theNCI⁩ ⁦@US_FDA⁩ industry academia tackling #trialdesign #biomarkers #immunooncology Report to follow ⁦⁦⁦⁦⁦@MoffittNews

ATarhiniMDPhD's tweet image. Pleasure to participate in ⁦⁦⁦@sitcancer⁩ #SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from ⁦@theNCI⁩ ⁦@US_FDA⁩ industry academia tackling
#trialdesign
#biomarkers
#immunooncology 
Report to follow 
⁦⁦⁦⁦⁦@MoffittNews⁩

I must be at the @franceintheus! An entire afternoon of trial design (and I went easy on the food this time😉😅) With @AlexMebazaa & friends.. #3CT #TrialDesign

hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign

Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO Wearable devices used to define “objective” fitness (OPS) in phase I trials 👉OPS (📸2) better predictor of OS than ECOG-PS (📸3) 🧐Actually, poor ECOG-PS and OPS correlation (📸4) 🔮⌚️#DigitalOncology for #TrialDesign

DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign
DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign
DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign
DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign

Excited to share our JCO paper “Objective Performance Status” (OPS), validated with wearables. We established a 1,200 m/day cutoff stratifies metastatic cancer survival (mOS 3.2/11.2;HR 5.76). Grateful to the team and @VicMorenoGarcia for his mentorship 🔗 ascopubs.org/doi/10.1200/OP…



Regulatory statistics is the backbone of #trialdesign for #drugdevelopment, biomarkers & devices. Our experts will help you determine the right sample size, optimal statistical design, appropriate endpoints and effective #randomization techniques. More: eu1.hubs.ly/H085QHj0

IDDI_Official's tweet image. Regulatory statistics is the backbone of #trialdesign for #drugdevelopment, biomarkers & devices. Our experts will help you determine the right sample size, optimal statistical design, appropriate endpoints and effective #randomization techniques. More: eu1.hubs.ly/H085QHj0

Thinking about advancing your career in #hepatologyresearch? This fall, join our online program to gain the skills to design, conduct & analyze research in #liverdisease—from foundations & efficient #trialdesign to #statisticalmachinelearning & #knowledgetranslation. Stay tuned!

ef_clif's tweet image. Thinking about advancing your career in #hepatologyresearch? This fall, join our online program to gain the skills to design, conduct & analyze research in #liverdisease—from foundations & efficient #trialdesign to #statisticalmachinelearning & #knowledgetranslation. Stay tuned!
ef_clif's tweet image. Thinking about advancing your career in #hepatologyresearch? This fall, join our online program to gain the skills to design, conduct & analyze research in #liverdisease—from foundations & efficient #trialdesign to #statisticalmachinelearning & #knowledgetranslation. Stay tuned!

Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!

DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!
DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!
DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!
DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!

#Opthalmologyclinicaltrials require special considerations at each stage. Our panel addresses advances in #trialdesign specific to genetic & #rarediseases of the eye, focusing on #cellandgenetherapy & the need to work collaboratively. Register today. xtalks.com/webinars/bring…

Fortrea's tweet image. #Opthalmologyclinicaltrials require special considerations at each stage. Our panel addresses advances in #trialdesign specific to genetic & #rarediseases of the eye, focusing on #cellandgenetherapy & the need to work collaboratively. Register today. 
xtalks.com/webinars/bring…
Fortrea's tweet image. #Opthalmologyclinicaltrials require special considerations at each stage. Our panel addresses advances in #trialdesign specific to genetic & #rarediseases of the eye, focusing on #cellandgenetherapy & the need to work collaboratively. Register today. 
xtalks.com/webinars/bring…

In #ACTEU's workshop today @GoldLabCharite discussed the priorities for a thriving #clinicaltrials landscape- good #trialdesign, principles-based guidance, appropriate infrastructure, continuous utilization. Join @MartinLandray tomorrow on ACTEU's support for multinational trials

goodtrials's tweet image. In #ACTEU's workshop today @GoldLabCharite discussed the priorities for a thriving #clinicaltrials landscape- good #trialdesign, principles-based guidance, appropriate infrastructure, continuous utilization. Join @MartinLandray tomorrow on ACTEU's support for multinational trials

Silva et al. explore a framework of solutions to enable a decentralized model for phase 1 clinical trials in this recent #JIPO review article @SilvajDiogo doi.org/10.36401/JIPO-… #trialdesign #clinicaltrials #phase1 #drugdevelopment

JIPOEditors's tweet image. Silva et al. explore a framework of solutions to enable a decentralized model for phase 1 clinical trials in this recent #JIPO review article @SilvajDiogo doi.org/10.36401/JIPO-… 
#trialdesign #clinicaltrials #phase1 #drugdevelopment

New year, new start. Early stage planning and considerations for the type of trial you want to run is critical. Plan early. #trialdesign #evidence #statistics #endpoints #clinicalresearch #clinicaldevelopment

aftdevelopment's tweet image. New year, new start. Early stage planning and considerations for the type of trial you want to run is critical. Plan early.

#trialdesign #evidence #statistics #endpoints #clinicalresearch #clinicaldevelopment

Prof Aoife Lowery @GalwayCMNHS talking about innovative #trialdesign in the area of #Cancer as part of the new Institute for #ClinicalTrials @aoifelowery 👏👏 speaking our language 🙏 #futuretrials

hrbtmrn's tweet image. Prof Aoife Lowery @GalwayCMNHS talking about innovative #trialdesign in the area of #Cancer as part of the new Institute for #ClinicalTrials @aoifelowery 👏👏 speaking our language 🙏 #futuretrials

As GLP-1 therapies gain traction, trials must evolve to support integrated, patient-centered care. Explore how multidisciplinary models can boost engagement and real-world impact: bit.ly/4frcADJ #PremierResearch #TrialDesign

premierresearch's tweet image. As GLP-1 therapies gain traction, trials must evolve to support integrated, patient-centered care. Explore how multidisciplinary models can boost engagement and real-world impact: bit.ly/4frcADJ

#PremierResearch   #TrialDesign

📢 WEBINAR ALERT: Join us on 20th Sept @ 14:00-16:00 Exploration of the Sequential Multiple Assignment Randomised Trial (SMART) design. Register now ➡️ hrb-tmrn.ie/training-educa… 📚💡 #trialsmethodology #trialdesign #Randomisation #clinicaltrials

hrbtmrn's tweet image. 📢 WEBINAR ALERT: 

Join us on 20th Sept @ 14:00-16:00 

Exploration of the Sequential Multiple Assignment Randomised Trial (SMART) design. 

Register now ➡️ hrb-tmrn.ie/training-educa… 📚💡 

#trialsmethodology #trialdesign #Randomisation #clinicaltrials

3 Surefire Ways To Design Trials That Patients Want And Need buff.ly/47gNu6x #clinicaltrials #trialdesign

mosio's tweet image. 3 Surefire Ways To Design Trials That Patients Want And Need buff.ly/47gNu6x 
#clinicaltrials #trialdesign

Second issue is the pitfall of composite PEP selection in which there is opposite treatment effect on the component endpoints. Even with a larger trial and/or higher event rates, overall treatment effect would be neutral. #TrialDesign


Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephtwitter @VladoPerkovic @GlomCon buff.ly/MGvRVem

Neph_Times's tweet image. Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephtwitter @VladoPerkovic @GlomCon buff.ly/MGvRVem

How patient-centric is your trial design... really? Take our quick 6-question audit to see how your approach stacks up against the new industry standard: tally.so/r/woJa6N #ClinOps #biotech #TrialDesign


Design Single-center randomized controlled trial; term neonates with PPHN ≤72h of life; 1:1 NNG vs control alongside standard care (oxygenation, ventilation, sildenafil, inotropes as needed). #TrialDesign #EvidenceBased


PURPOSE 1 & 2: bHIV matches low-adherence HIV rates, more closely in cis women than MSM/TGW—highlighting how population & behavior can skew estimates. Elegant work @JjParienti supporting bHIV as a robust, ethical comparator in PrEP trials. #HIV #PrEP #TrialDesign


As GLP-1 therapies gain traction, trials must evolve to support integrated, patient-centered care. Explore how multidisciplinary models can boost engagement and real-world impact: bit.ly/4frcADJ #PremierResearch #TrialDesign

premierresearch's tweet image. As GLP-1 therapies gain traction, trials must evolve to support integrated, patient-centered care. Explore how multidisciplinary models can boost engagement and real-world impact: bit.ly/4frcADJ

#PremierResearch   #TrialDesign

New to rare‑disease research or a data junkie? IDDI’s experts show why smart trial design isn’t just ticking a regulatory box, it’s what makes or breaks studies when every patient counts. Watch it now: lnkd.in/gUyNtHEn #CTFAPartner#TrialDesign #RareDiseases


I must be at the @franceintheus! An entire afternoon of trial design (and I went easy on the food this time😉😅) With @AlexMebazaa & friends.. #3CT #TrialDesign

hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign

16/ Cross-overs are not just messy data—they’re design choices that shape trial conclusions. Understand them. Scrutinize them. And don’t let them hijack your outcomes. 📊🔍 #RCT #EBM #TrialDesign #MedTwitter


Traditional trial design is leaving valuable data on the table. Learn how one company's eGFR criteria shift changed everything." #TrialDesign #ClinicalResearch #DataOptimization


Fascinating question, Dr. Loong! ⏱️ Timing might just be the hidden variable in ICI outcomes. More research into circadian rhythm and infusion timing could unlock serious insights! 🔄💉 #ASCO25 #Immunotherapy #TrialDesign


Behind every successful clinical trial is a strong early-phase strategy. Protocol design, endpoints & timelines set the tone for everything ahead. Build it right, from the start. Talk to our experts: credevo.odoo.com/r/n04 #ClinicalDevelopment #TrialDesign

gocredevo's tweet image. Behind every successful clinical trial is a strong early-phase strategy. Protocol design, endpoints & timelines set the tone for everything ahead. Build it right, from the start.

Talk to our experts: credevo.odoo.com/r/n04

#ClinicalDevelopment #TrialDesign

2️⃣Biased In, Biased Out Drug development is being re-engineered by code. AI is powering: 🔬 #Biomarkerdiscovery 📈 #Drugprediction models ⚙️ #Trialdesign But the data feeding these systems? Still mostly Caucasian. Still mostly Western. Still dangerously incomplete.

PaiconAI's tweet image. 2️⃣Biased In, Biased Out

Drug development is being re-engineered by code.

AI is powering: 
🔬 #Biomarkerdiscovery 
📈 #Drugprediction models
⚙️ #Trialdesign

But the data feeding these systems?
Still mostly Caucasian. 
Still mostly Western. 
Still dangerously incomplete.

DAOH keeps trials clear and to the point. Properly powered RCTs focus on precision, not inflated effects. #TrialDesign


What difference does it make to analyse a crossover trial as a parallel-group trial? Data from doi.org/10.1007/s00394… 24 hours of a low-carbohydrate diet on fasting glucose concentrations @AaronHengist #lowcarb #science #trialdesign #stats

Gonzalez_JT's tweet image. What difference does it make to analyse a crossover trial as a parallel-group trial?  

Data from doi.org/10.1007/s00394…

24 hours of a low-carbohydrate diet on fasting glucose concentrations

@AaronHengist 

#lowcarb #science #trialdesign #stats

Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephtwitter @VladoPerkovic @GlomCon buff.ly/MGvRVem

Neph_Times's tweet image. Vlado Perkovic shared his thoughts on glomerular disease clinical trial design, a topic on which he presented at #GlomConHawaii. #trialdesign #kidneydisease #glomerulardisease #nephrology #nephtwitter @VladoPerkovic @GlomCon buff.ly/MGvRVem

Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!

DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!
DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!
DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!
DrAnaCapuano's tweet image. Amazing organization today of #AAICNeuro Chicago Hub. In the workshop I introduced #biostatistics & #TrialDesign  in non pharmacological trials in dementia & learner about the amazing work being done in this space. The morning sessions are available on demand for 30 days!

How’s this for a view? Thank you @AlexMebazaa for the opportunity! #TrialDesign #Evidence #AnalyticPlans #Implementation #3CT #DC #NationalMall #Views

hvanspall's tweet image. How’s this for a view?

Thank you @AlexMebazaa for the opportunity!

#TrialDesign #Evidence #AnalyticPlans #Implementation #3CT 
#DC #NationalMall #Views

#3CT Clinical Trialists Meeting in DC chaired by @AlexMebazaa Jun 13-15 Excited to present 💠outcome selection in #Implementation RCTs 💠considerations around using #WinRatio in #RCT analysis Excited to learn from friends 3ctmeeting.com #TrialDesign #ResearchMethods

hvanspall's tweet image. #3CT Clinical Trialists Meeting in DC chaired by @AlexMebazaa Jun 13-15

Excited to present
💠outcome selection in #Implementation RCTs
💠considerations around using #WinRatio in #RCT analysis

Excited to learn from friends
3ctmeeting.com

#TrialDesign #ResearchMethods


Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO Wearable devices used to define “objective” fitness (OPS) in phase I trials 👉OPS (📸2) better predictor of OS than ECOG-PS (📸3) 🧐Actually, poor ECOG-PS and OPS correlation (📸4) 🔮⌚️#DigitalOncology for #TrialDesign

DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign
DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign
DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign
DrAngelaLamarca's tweet image. Data from @Hospital_FJD + @TheSTARTCenter at @JCOOP_ASCO 

Wearable devices used to define “objective” fitness (OPS) in phase I trials

👉OPS (📸2) better predictor of OS than ECOG-PS (📸3)
🧐Actually, poor ECOG-PS and OPS correlation (📸4)

🔮⌚️#DigitalOncology for #TrialDesign

Excited to share our JCO paper “Objective Performance Status” (OPS), validated with wearables. We established a 1,200 m/day cutoff stratifies metastatic cancer survival (mOS 3.2/11.2;HR 5.76). Grateful to the team and @VicMorenoGarcia for his mentorship 🔗 ascopubs.org/doi/10.1200/OP…



Thinking about advancing your career in #hepatologyresearch? This fall, join our online program to gain the skills to design, conduct & analyze research in #liverdisease—from foundations & efficient #trialdesign to #statisticalmachinelearning & #knowledgetranslation. Stay tuned!

ef_clif's tweet image. Thinking about advancing your career in #hepatologyresearch? This fall, join our online program to gain the skills to design, conduct & analyze research in #liverdisease—from foundations & efficient #trialdesign to #statisticalmachinelearning & #knowledgetranslation. Stay tuned!
ef_clif's tweet image. Thinking about advancing your career in #hepatologyresearch? This fall, join our online program to gain the skills to design, conduct & analyze research in #liverdisease—from foundations & efficient #trialdesign to #statisticalmachinelearning & #knowledgetranslation. Stay tuned!

Silva et al. explore a framework of solutions to enable a decentralized model for phase 1 clinical trials in this recent #JIPO review article @SilvajDiogo doi.org/10.36401/JIPO-… #trialdesign #clinicaltrials #phase1 #drugdevelopment

JIPOEditors's tweet image. Silva et al. explore a framework of solutions to enable a decentralized model for phase 1 clinical trials in this recent #JIPO review article @SilvajDiogo doi.org/10.36401/JIPO-… 
#trialdesign #clinicaltrials #phase1 #drugdevelopment

This approach can be adopted within phase 3 trials. Trialists should address regulatory, payer, institution, clinician, patient requirements within the phase 3 trial design so that the #evidence generated is fit for purpose👇🏽 3/ authors.elsevier.com/a/1k2Nc2d9GH%7… #TrialDesign

hvanspall's tweet image. This approach can be adopted within phase 3 trials. 

Trialists should address regulatory, payer, institution, clinician, patient requirements within the phase 3 trial design so that the #evidence generated is fit for purpose👇🏽

3/
authors.elsevier.com/a/1k2Nc2d9GH%7…
#TrialDesign

Prof Aoife Lowery @GalwayCMNHS talking about innovative #trialdesign in the area of #Cancer as part of the new Institute for #ClinicalTrials @aoifelowery 👏👏 speaking our language 🙏 #futuretrials

hrbtmrn's tweet image. Prof Aoife Lowery @GalwayCMNHS talking about innovative #trialdesign in the area of #Cancer as part of the new Institute for #ClinicalTrials @aoifelowery 👏👏 speaking our language 🙏 #futuretrials

In #ACTEU's workshop today @GoldLabCharite discussed the priorities for a thriving #clinicaltrials landscape- good #trialdesign, principles-based guidance, appropriate infrastructure, continuous utilization. Join @MartinLandray tomorrow on ACTEU's support for multinational trials

goodtrials's tweet image. In #ACTEU's workshop today @GoldLabCharite discussed the priorities for a thriving #clinicaltrials landscape- good #trialdesign, principles-based guidance, appropriate infrastructure, continuous utilization. Join @MartinLandray tomorrow on ACTEU's support for multinational trials

New year, new start. Early stage planning and considerations for the type of trial you want to run is critical. Plan early. #trialdesign #evidence #statistics #endpoints #clinicalresearch #clinicaldevelopment

aftdevelopment's tweet image. New year, new start. Early stage planning and considerations for the type of trial you want to run is critical. Plan early.

#trialdesign #evidence #statistics #endpoints #clinicalresearch #clinicaldevelopment

#Opthalmologyclinicaltrials require special considerations at each stage. Our panel addresses advances in #trialdesign specific to genetic & #rarediseases of the eye, focusing on #cellandgenetherapy & the need to work collaboratively. Register today. xtalks.com/webinars/bring…

Fortrea's tweet image. #Opthalmologyclinicaltrials require special considerations at each stage. Our panel addresses advances in #trialdesign specific to genetic & #rarediseases of the eye, focusing on #cellandgenetherapy & the need to work collaboratively. Register today. 
xtalks.com/webinars/bring…
Fortrea's tweet image. #Opthalmologyclinicaltrials require special considerations at each stage. Our panel addresses advances in #trialdesign specific to genetic & #rarediseases of the eye, focusing on #cellandgenetherapy & the need to work collaboratively. Register today. 
xtalks.com/webinars/bring…

📢 WEBINAR ALERT: Join us on 20th Sept @ 14:00-16:00 Exploration of the Sequential Multiple Assignment Randomised Trial (SMART) design. Register now ➡️ hrb-tmrn.ie/training-educa… 📚💡 #trialsmethodology #trialdesign #Randomisation #clinicaltrials

hrbtmrn's tweet image. 📢 WEBINAR ALERT: 

Join us on 20th Sept @ 14:00-16:00 

Exploration of the Sequential Multiple Assignment Randomised Trial (SMART) design. 

Register now ➡️ hrb-tmrn.ie/training-educa… 📚💡 

#trialsmethodology #trialdesign #Randomisation #clinicaltrials

Pleasure to participate in ⁦⁦⁦@sitcancer#SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from ⁦@theNCI⁩ ⁦@US_FDA⁩ industry academia tackling #trialdesign #biomarkers #immunooncology Report to follow ⁦⁦⁦⁦⁦@MoffittNews

ATarhiniMDPhD's tweet image. Pleasure to participate in ⁦⁦⁦@sitcancer⁩ #SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from ⁦@theNCI⁩ ⁦@US_FDA⁩ industry academia tackling
#trialdesign
#biomarkers
#immunooncology 
Report to follow 
⁦⁦⁦⁦⁦@MoffittNews⁩

3 Surefire Ways To Design Trials That Patients Want And Need buff.ly/47gNu6x #clinicaltrials #trialdesign

mosio's tweet image. 3 Surefire Ways To Design Trials That Patients Want And Need buff.ly/47gNu6x 
#clinicaltrials #trialdesign

I must be at the @franceintheus! An entire afternoon of trial design (and I went easy on the food this time😉😅) With @AlexMebazaa & friends.. #3CT #TrialDesign

hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign
hvanspall's tweet image. I must be at the @franceintheus! 
An entire afternoon of trial design (and I went easy on the food this time😉😅)
With @AlexMebazaa & friends.. 
#3CT #TrialDesign

#MedidataNEXT #London is nearly here! Join @stales & @Parexel's Xoli Belgrave for @Medidata’s mainstage session exploring how we can improve #TrialDesign & promote equity in #ClinicalTrials. Register now: mdso.io/v9v

georgebiski's tweet image. #MedidataNEXT #London is nearly here! Join @stales & @Parexel's Xoli Belgrave for @Medidata’s mainstage session exploring how we can improve #TrialDesign & promote equity in #ClinicalTrials. Register now: mdso.io/v9v

Loading...

Something went wrong.


Something went wrong.


United States Trends